{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:56:13Z","timestamp":1769169373285,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Antipseudomonal antibiotics should be restricted to patients at risk of <jats:italic>Pseudomonas aeruginosa<\/jats:italic> infection. However, the indications in different guidelines on community-acquired pneumonia (CAP) are discordant. Our objectives were to\u00a0assess the prevalence of antipseudomonal antibiotic prescriptions and to identify determinants of empirical antibiotic choices in the emergency department.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Observational,\u00a0retrospective, one-year cohort study in hospitalized adults with pneumonia. Antibiotic choices and clinical and demographic data were recorded on a standardized form. Antibiotics with antipseudomonal activity were classified into two groups: a) \u03b2-lactam antipseudomonals (\u03b2-APS), including carbapenems, piperacillin \/ tazobactam or cefepime (in monotherapy or combination) and b) monotherapy with antipseudomonal quinolones.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Data were recorded from 549 adults with pneumonia, with <jats:italic>Pseudomonas aeruginosa<\/jats:italic> being isolated in only nine (1.6%). Most (85%) prescriptions were compliant with SEPAR guidelines and 207 (37%) patients received antibiotics with antipseudomonal activity (14% \u03b2-APS and 23% levofloxacin). The use of \u03b2-APS was independently associated with ICU admission (OR 8.16 95% CI 3.69\u201318.06) and prior hospitalization (OR 6.76 95% CI 3.02\u201315.15), while levofloxacin was associated with negative pneumococcal urine antigen tests (OR 3.41 95% CI 1.70\u20136.85) but negatively associated with ICU admission (OR 0.26 95% CI 0.08\u20130.86). None of these factors were associated with <jats:italic>P aeruginosa<\/jats:italic> episodes. In univariate analysis, prior <jats:italic>P aeruginosa<\/jats:italic> infection\/colonization (2\/9 vs 6\/372, <jats:italic>p<\/jats:italic>\u00a0=\u20090.013), severe COPD (3\/9 vs 26\/372, <jats:italic>p<\/jats:italic>\u00a0=\u20090.024), multilobar involvement (7\/9 vs 119\/372, <jats:italic>p<\/jats:italic>\u00a0=\u20090.007) and prior antibiotic (6\/9 vs 109\/372, <jats:italic>p<\/jats:italic>\u00a0=\u20090.025) were significantly associated with <jats:italic>P aeruginosa<\/jats:italic> episodes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Antipseudomonal prescriptions\u00a0were common, in spite of the very low incidence\u00a0of <jats:italic>Pseudomonas aeruginosa<\/jats:italic>. The rationale for prescription was influenced by both severity-of-illness and pneumococcal urine antigen test (levofloxacin) and prior hospitalization and ICU admission (\u03b2-APS). However, these factors were not associated with <jats:italic>P aeruginosa<\/jats:italic> episodes. Only prior <jats:italic>P aeruginosa<\/jats:italic> infection\/colonization and severe COPD seem to be reliable indicators in clinical practice.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12890-020-1115-0","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T14:02:49Z","timestamp":1585922569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Determinants of empirical antipseudomonal antibiotic prescription for adults with pneumonia in the emergency department"],"prefix":"10.1186","volume":"20","author":[{"given":"Nuria","family":"Angrill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8882-4033","authenticated-orcid":false,"given":"Miguel","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli","family":"Font","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Vall\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisi","family":"Mor\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Mons\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"1115_CR1","doi-asserted-by":"publisher","first-page":"S27e72","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27e72.","journal-title":"Clin Infect Dis"},{"key":"1115_CR2","doi-asserted-by":"publisher","first-page":"E1e59","DOI":"10.1111\/j.1469-0691.2011.03602.x","volume":"17","author":"M Woodhead","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Leven M, et al. Guidelines for the management of adult lower respiratory tract infections full version. Clin Microbiol Infect. 2011;17:E1e59.","journal-title":"Clin Microbiol Infect"},{"key":"1115_CR3","doi-asserted-by":"publisher","first-page":"iii1e55","DOI":"10.1136\/thx.2009.121434","volume":"64","author":"WS Lim","year":"2009","unstructured":"Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64:iii1e55.","journal-title":"Thorax"},{"issue":"5","key":"1115_CR4","first-page":"272","volume":"41","author":"I Alfageme","year":"2005","unstructured":"Alfageme I, Aspa J, Bello S, Blanquer J, Blanquer R, Border\u00edas L, et al. Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2005;41(5):272\u201389.","journal-title":"Arch Bronconeumol"},{"key":"1115_CR5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","volume":"386","author":"E Prina","year":"2015","unstructured":"Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015;386:1097\u2013108.","journal-title":"Lancet"},{"key":"1115_CR6","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMra1312885","volume":"371","author":"DM Musher","year":"2014","unstructured":"Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371:1619\u201328.","journal-title":"N Engl J Med"},{"key":"1115_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.rmed.2007.04.018","volume":"101","author":"S Reyes Calzada","year":"2007","unstructured":"Reyes Calzada S, Martinez Tomas R, Cremades Romero MJ, Martinez Moragon E, Soler Cataluna JJ, Menendez Villanueva R. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Respir Med. 2007;101:1909\u201315.","journal-title":"Respir Med"},{"issue":"4","key":"1115_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/cid\/cir848","volume":"54","author":"MH Kollef","year":"2012","unstructured":"Kollef MH, Micek ST. Patients hospitalized with pneumonia: determining the need for broad-spectrum antibiotic therapy. Clin Infect Dis. 2012;54(4):479\u201382.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1115_CR9","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1086\/498119","volume":"41","author":"M Bod\u00ed","year":"2005","unstructured":"Bod\u00ed M, Rodr\u00edguez A, Sol\u00e9-Viol\u00e1n J, Gilavert MC, Garnacho J, Blanquer J, et al. Community-acquired pneumonia intensive care units (CAPUCI) study investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005;41(12):1709\u201316.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1115_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-2600(13)70084-5","volume":"1","author":"A Singanayagam","year":"2013","unstructured":"Singanayagam A, Chalmers JD. Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respir Med. 2013;1(8):653\u201362.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1115_CR11","doi-asserted-by":"publisher","first-page":"1900057","DOI":"10.1183\/13993003.00057-2019","volume":"54","author":"BJ Webb","year":"2019","unstructured":"Webb BJ, Sorensen J, Jephson A, Mecham I, Dean NC. Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study. Eur Respir J. 2019;54(1):1900057.","journal-title":"Eur Respir J"},{"key":"1115_CR12","unstructured":"Respipedia. Respiratory infections. Pseudomonas aeruginosa infections. Www.Ers-education.Org\/home\/browse-all-content.Aspx?Idparent=207389. Date last Accessed: 31 Jan 2019."},{"issue":"16","key":"1115_CR13","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/archinte.162.16.1849","volume":"162","author":"F Arancibia","year":"2002","unstructured":"Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002;162(16):1849\u201358.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1115_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10096-008-0485-7","volume":"27","author":"CI Kang","year":"2008","unstructured":"Kang CI, Song JH, Oh WS, Ko KS, Chung DR. Peck KR; Asian network for surveillance of resistant pathogens (ANSORP) study group. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. Eur J Clin Microbiol Infect Dis. 2008;27(8):657\u201361.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"1115_CR15","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1183\/09031936.00091809","volume":"35","author":"H von Baum","year":"2010","unstructured":"von Baum H, Welte T, Marre R, Suttorp N, Ewig S, CAPNETZ study group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J. 2010;35(3):598\u2013605.","journal-title":"Eur Respir J"},{"key":"1115_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1440-1843.2008.01371.x","volume":"14","author":"M Falguera","year":"2009","unstructured":"Falguera M, Carratala J, Ruiz-Gonzalez A, Garcia-Vidal C, Gazquez I, Dorca J, et al. Risk factors and outcome of community-acquired pneumonia due to gram-negative bacilli. Respirology. 2009;14:105\u201311.","journal-title":"Respirology"},{"key":"1115_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/resp.12506","volume":"20","author":"O Sibila","year":"2015","unstructured":"Sibila O, Laserna E, Maselli DJ, Fernandez JF, Mortensen EM, Anzueto A, et al. Risk factors and antibiotic therapy in P aeruginosa community-acquired pneumonia. Respirology. 2015;20:660\u20136.","journal-title":"Respirology"},{"key":"1115_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.chest.2016.03.042","volume":"150","author":"C Cilloniz","year":"2016","unstructured":"Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, et al. Community-acquired pneumonia due to multidrug- and non-multidrug-resistant pseudomonas aeruginosa. Chest. 2016;150:415\u201325.","journal-title":"Chest"},{"issue":"7","key":"1115_CR19","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","volume":"163","author":"MS Niederman","year":"2001","unstructured":"Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730\u201354.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1115_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cir840","volume":"54","author":"S Aliberti","year":"2012","unstructured":"Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012;54(4):470\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1115_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","volume":"176","author":"KF Rabe","year":"2007","unstructured":"Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532\u201355.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1115_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society; Infectious Diseases Society of America","year":"2005","unstructured":"American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1115_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s00134-014-3239-2","volume":"40","author":"J Vall\u00e9s","year":"2014","unstructured":"Vall\u00e9s J, Martin-Loeches I, Torres A, Diaz E, Seijas I, L\u00f3pez MJ, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med. 2014;40(4):572\u201381.","journal-title":"Intensive Care Med"},{"issue":"5","key":"1115_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"5","key":"1115_CR25","first-page":"297","volume":"30","author":"F Oltra Hostalet","year":"2018","unstructured":"Oltra Hostalet F, N\u00fa\u00f1ez-N\u00fa\u00f1ez M, Portillo Cano MDM, Navarro Bustos C, Rodr\u00edguez-Ba\u00f1o J, Retamar Gentil P. Analysis of quality antimicrobial agent use in the emergency department of a tertiary care hospital. Emergencias. 2018;30(5):297\u2013302.","journal-title":"Emergencias."},{"issue":"10","key":"1115_CR26","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/j.rmed.2007.05.011","volume":"101","author":"R Pifarre","year":"2007","unstructured":"Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med. 2007;101(10):2139\u201344.","journal-title":"Respir Med"},{"issue":"5","key":"1115_CR27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.5811\/westjem.2017.5.33901","volume":"18","author":"BA Faine","year":"2017","unstructured":"Faine BA, Mohr N, Dietrich J, Meadow L, Harland KK, Chrischilles E. Antimicrobial therapy for pneumonia in the emergency department: the impact of clinical pharmacists on appropriateness. West J Emerg Med. 2017;18(5):856\u201363. https:\/\/doi.org\/10.5811\/westjem.2017.5.33901.","journal-title":"West J Emerg Med"},{"issue":"1","key":"1115_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1183\/13993003.00191-2016","volume":"48","author":"A Liapikou","year":"2016","unstructured":"Liapikou A, Cill\u00f3niz C, Gabarr\u00fas A, Amaro R, De la Bellacasa JP, Mensa J, et al. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. Eur Respir J. 2016;48(1):257\u201361.","journal-title":"Eur Respir J"},{"issue":"1","key":"1115_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1378\/chest.08-1216","volume":"135","author":"T Lisboa","year":"2009","unstructured":"Lisboa T, Blot S, Waterer GW, Canalis E, de Mendoza D, Rodriguez A, et al. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest. 2009;135(1):165\u201372.","journal-title":"Chest"},{"key":"1115_CR30","first-page":"2(4)","volume":"19","author":"DM West","year":"2016","unstructured":"West DM, McCauley LM, Sorensen JS, Jephson AR, Dean NC. Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals. ERJ Open Res. 2016;19:2(4).","journal-title":"ERJ Open Res"},{"key":"1115_CR31","doi-asserted-by":"publisher","first-page":"j2471","DOI":"10.1136\/bmj.j2471","volume":"358","author":"RG Wunderink","year":"2017","unstructured":"Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.","journal-title":"BMJ"},{"issue":"8","key":"1115_CR32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1017\/ice.2017.98","volume":"38","author":"BE Jones","year":"2017","unstructured":"Jones BE, Brown KA, Jones MM, Huttner BD, Greene T, Sauer BC, et al. Variation in empiric coverage versus detection of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in hospitalizations for community-onset pneumonia across 128 US veterans affairs medical centers. Infect Control Hosp Epidemiol. 2017;38(8):937\u201344.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"1115_CR33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/cid\/civ074","volume":"60","author":"JD Chalmers","year":"2015","unstructured":"Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysispublished correction appears in. Clin Infect Dis. 2015;60(7):1143.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1115_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/resp.12651","volume":"21","author":"ML Metersky","year":"2016","unstructured":"Metersky ML, Frei CR, Mortensen EM. Predictors of pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology. 2016;21(1):157\u201363.","journal-title":"Respirology."},{"key":"1115_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/thx.2010.143982","volume":"66","author":"C Cilloniz","year":"2011","unstructured":"Cilloniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrus A, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66:340\u20136.","journal-title":"Thorax"},{"issue":"4","key":"1115_CR36","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","volume":"36","author":"I Martin-Loeches","year":"2010","unstructured":"Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36(4):612\u201320.","journal-title":"Intensive Care Med"},{"issue":"1","key":"1115_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.00054108","volume":"33","author":"MI Restrepo","year":"2009","unstructured":"Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33(1):153\u20139.","journal-title":"Eur Respir J"},{"key":"1115_CR38","first-page":"1","volume":"28","author":"A Tabah","year":"2019","unstructured":"Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) critically ill patients study group (ESGCIP). Intensive Care Med. 2019;28:1\u201321.","journal-title":"Intensive Care Med"},{"issue":"9","key":"1115_CR39","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/civ629","volume":"61","author":"BE Jones","year":"2015","unstructured":"Jones BE, Jones MM, Huttner B, Stoddard G, Brown KA, Stevens VW, et al. Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis. 2015;61(9):1403\u201310.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1115_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","volume":"12","author":"E Prina","year":"2015","unstructured":"Prina E, Ranzani OT, Polverino E, Cill\u00f3niz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153\u201360.","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"1115_CR41","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1128\/AAC.02582-14","volume":"58","author":"AE Gross","year":"2014","unstructured":"Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother. 2014;58(9):5262\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1115_CR42","doi-asserted-by":"crossref","unstructured":"Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018;52:1701190.","DOI":"10.1183\/13993003.01190-2017"},{"issue":"7","key":"1115_CR43","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-020-1115-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T23:08:40Z","timestamp":1617404920000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-1115-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1115"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-1115-0","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"17 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Hospital Ethics Committee on Human Research (No. 2014\/538). The need for informed consent was waived because patient information was anonymized and de-identified prior to analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JR has received research grants and consulting fees from BAYER and PARATEK. The pharmaceutical industry did not contribute to the funding of this study. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}